2-(2,6-dimethylphenyl)-N'-hydroxy-3-(4-hydroxyphenyl)-1H-indole-1-carboximidamide | 1288963-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-(2,6-dimethylphenyl)-N'-hydroxy-3-(4-hydroxyphenyl)-1H-indole-1-carboximidamide
• 英文别名: 2-(2,6-dimethylphenyl)-N'-hydroxy-3-(4-hydroxyphenyl)indole-1-carboximidamide
• CAS: 1288963-29-0
• 化学式: C₂₃H₂₁N₃O₂
• 分子量: 371.439
• InChiKey: NPVOWFUAVBKKLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• NOVEL ESTROGEN RECEPTOR LIGANDS
  申请人：Wennerstål Mattias

  公开号：US20120202861A1

  公开（公告）日：2012-08-09

  The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. Formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are as defined in the specification.

  该发明提供了一种式(I)的化合物或药用可接受的酯、酰胺、溶剂合物或盐，包括此类酯或酰胺的盐，以及此类酯、酰胺或盐的溶剂合物。该发明还提供了这些化合物在治疗或预防与雌激素受体活性相关的疾病或紊乱的条件中的使用。式(I)中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如规范中所定义。
• Estrogen receptor ligand treatment for neurodegenerative diseases
  申请人：The Regents of the University of California

  公开号：US10758496B2

  公开（公告）日：2020-09-01

  The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

  本发明涉及使用雌激素受体β（ERβ）配体治疗神经系统疾病，如多发性硬化症（MS）和阿尔茨海默病。
• ESTROGEN RECEPTOR LIGANDS
  申请人：Karo Pharma AB

  公开号：EP2486010B1

  公开（公告）日：2019-06-12
• ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES
  申请人：The Regents of the University of California

  公开号：EP3189026A1

  公开（公告）日：2017-07-12
• US8710243B2
  申请人：——

  公开号：US8710243B2

  公开（公告）日：2014-04-29